This finding is consistent with that of Muralidharan R et al, who found that targeted inhibition of HuR in cancer cells suppresses several HuR-regulated oncoproteins, increasing anticancer treatment efficacy (Muralidharan et al., 2016). Here, ELAVL1 is linked to cancer.